Topic:

Partnering

Latest Headlines

Latest Headlines

Quintiles taps Google partner Tute Genomics for R&D

Quintiles, the world's largest CRO, has reached out to startup Tute Genomics for access to its database of 8.5 billion annotations of genetic variants.

Google's mystery biotech Calico partners with the Broad on aging-related drugs

Slowly but surely, Google's star-driven biotech Calico is laying the foundation for what promises to be a major biotech focused on some of the biggest diseases that limit longevity. There's a Big Pharma partnership with AbbVie, a development deal down in Texas and now it's time to team up with top scientists. Earlier in the week Harvard and MIT's renowned Broad Institute signed on to work with Calico on pushing new therapies into the clinic.

PPD cozies up to trial site group with an eye on enrollment

PPD's Acurian subsidiary has expanded its relationship with the Society for Clinical Research Sites, a group representing thousands of trial outposts around the globe, focusing on improving patient recruitment.

Daiichi Sankyo pays $200M to AstraZeneca for Movantik U.S. sales rights

AstraZeneca announced a partnership with Daiichi Sankyo to sell its opioid-induced constipation therapy Movantik in the U.S. for a $200 million upfront fee from the Japanese drugmaker followed by sales-related payments of up to $625 million.

Catalent shakes up its business with an eye on product launches

Catalent is merging a few of its core business units in hopes of better focusing on getting its clients' drugs onto the market and pulling off smooth launches.

GSK to test Ebola jab with booster from Emergent BioSolutions

GlaxoSmithKline is testing its Ebola jab in Africa to see if it provokes an immune response strong enough to successfully beat an Ebola infection. But if it turns out to be too weak, never fear--the Big Pharma has a plan. It's teaming up with Maryland-based Emergent BioSolutions to test the latter's Ebola shot as a booster for its own vaccine.

Evotec pairs up with Second Genome to gut out some R&D

Hybrid researcher Evotec has signed a deal with microbiomics biotech Second Genome to lend out its drug discovery capabilities in hopes of crafting treatments that harness the power of the gut.

Soon-Shiong's NantWorks deepens its immuno-oncology ties with Sorrento

Billionaire biotech entrepreneur Patrick Soon-Shiong is expanding his company's relationship with Sorrento Therapeutics, promising $110 million in cash and equity in exchange for the rights to some cancer-fighting immunotherapies.

Galapagos registers another setback as J&J dumps anti-inflammatory pact

Eight years after J&J handed over €15 million in an upfront payment to Galapagos to launch a partnership to develop anti-inflammatory drugs, the pharma giant is bowing out--the latest in a series of development setbacks at the European biotech.

Depomed picks up loan for second half of $1.05B Nucynta acquisition from J&J

After securing U.S. rights to Janssen's Nucynta franchise in mid-January this year, Depomed has now raised enough to pay for it in full. Nucynta fits nicely into Depomed's cadre of pain and neurological treatments, and the Newark, CA-based company's Acuform drug delivery tech already gives Nucynta an edge as an oral treatment.